Navigation Links
Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change!
Date:3/19/2011

1; making it arguably the most potent such compound under development. Rx100 protects against damage to both the bone marrow as well as the critical cells of the small intestine.

Testing of Rx100 has demonstrated its unique properties in comparison to other drug candidates in the pipeline. Of significance is the fact that Rx100: a) is a small molecule, b) is essentially nontoxic at therapeutic doses, c) has a long shelf life, d) is nonimmunogenic, e) and provides effective treatment of ARS when administered up to 72 hours after exposure to lethal, whole-body radiation.

Dr. W. Shannon McCool, RxBio's CEO, points out that: "Rx100 is unique among radioprotectants / radiomitigators in that it boosts natural mechanisms that promote and sustain cell survival in almost every cell type and at the same time inhibits the cascade leading to programmed cell death (apoptosis). Thus, Rx100 augments the good and shuts down the bad. While other products shut down essential cellular signaling mechanisms involved in radiation-induced cellular injury and tend to lack specificity and/or may be toxic, Rx100 is a specific activator of natural, nontoxic, protective mechanisms of cell survival and antiapoptosis. Among its actions, Rx100 protects critical stem cells. Rx100 can be formulated for a wide range of patient types – from infants to the elderly – and can be administered either orally or subcutaneously."

In addition, Dr. Gabor Tigyi, RxBio's CSO, comments that: "Rx100 is a potent protector of the GI tract. This drug provides significant protection to the gut from radiation as well as other toxic substances such as cholera toxin. Among its actions, Rx100 maintains the mucosal barrier of the GI tract. It prevents severe diarrhea and the entry of bacterial toxins into the blood stream – both potentially severe side effects." RxBio has recently presented it's initial NHP data at the BARDA meeting that took place in January, 2011, in Washington. Th
'/>"/>

SOURCE RxBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
2. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
3. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
4. ChemImage Works to Improve Existing Methods of Imaging Untreated Fingerprints on Paper Substrates
5. Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
6. Australian Patent Issued to CreAgri® for Ultraviolet Radiation (UVR) Protection by its Hydroxytyrosol-Based Formulations
7. Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome
8. Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation!
9. Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference
10. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
11. New near-field radiation therapy promises relief for overheating laptops
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Finnish-Swedish research group at the Institute for Molecular ... institutet, Stockholm, has developed a novel "man and ... This innovative diagnostic aid was described in ... The method is based on computer vision algorithms ... combined with visualization of only the diagnostically most ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 His Majesty ... Opening , The Court of His Majesty Willem-Alexander, King ... attend the Grand Opening of POET-DSM Advanced Biofuels’ Project ... Sept. 3. , The King will take part in ... activity, scheduled for 11 a.m.-12:20 p.m. and tour the ...
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary Dynamics ... Jeffrey Epstein VI Foundation , have shown that the ... elimination. These aggressive cells are the driver mutations that drive ... of what to look for when examining tumors, comes at ... can be extracted from biopsy, it,s very difficult to know ...
(Date:8/21/2014)... Pursuit Solutions ( http://www.pursuit-solutions.com ), ... services for Life Sciences sales and marketing organizations, ... New Commercial Sales Models” by Peter Robinson, co-founder ... article examines some innovative models used to improve ... in the pharmaceutical market. Robinson grades the industry ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... A new expert analysis in Nature Nanotechnology ... lessons learned from past technologies to ensure the safe ... , The study applies the 12 "late lessons from ... in 2001, to the emerging field of nanotechnology. ...
... July 21 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,(Lorus), a biopharmaceutical ... and technologies for the management,of cancer, today reported financial ... 2008. Unless specified otherwise, all amounts are in Canadian,dollars., ... of GLP toxicology studies for Lorus, lead anticancer small ...
... KENILWORTH, N.J., July 21 Schering-Plough,Corporation (NYSE: ... conference call and,webcast to review the sales and ... 4:45 p.m. (EDT) from 8 a.m. today. The ... 2008, after the close of,the New York Stock ...
Cached Biology Technology:Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 2Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 3Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 4Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 5Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 6Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 7Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 8Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today 2
(Date:8/21/2014)... in smog-producing toxins in past decade, GTA still ... shows that while the Greater Toronto Area (GTA) ... contribute to smog, the city continues to violate ... which can cause or aggravate health problems such ... by a set of complex photochemical reactions involving ...
(Date:8/21/2014)... fungus linked to dandruff, eczema and other itchy, flaky ... further global reachesincluding Hawaiian coral reefs and the extreme ... A review in the scientific journal PLOS Pathogens ... fungi of the genus Malassezia in light ... from around the world. , University of Hawai,i at ...
(Date:8/21/2014)... Fram Strait is a key region in the global oceanic ... and Svalbard warm Atlantic water flows to the north into ... water masses and sea ice push their way out of ... the Atlantic water cools here on its way to the ... water caused in this manner drives the global band of ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... available in German . , In emerging ... dramatically. Indeed, worldwide consumption of red meat has quadrupled since ... increasing prosperity to lead to a doubling of global meat ... planet, with its limited farmland resources, will still be able ...
... international team of researchers led by Daniel J. ... for Translational Medicine and Therapeutics, has received a ... to study the molecular genetics of atherosclerotic cardiovascular ... Genes Associated with Plasma Lipids and Cardiovascular Disease," ...
... equity fund that specializes in making concentrated investments ... is co-managed by Philip Sassower, CEO, and Andrea ... Chairman and CEO, while Mr. Goren is the ... StatementsCertain statements contained in this press release, including ...
Cached Biology News:Eating low-fat, thanks to lupin proteins 2Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
... of your microarray data using Asuragens ... you need from consultation to extensive ... to date methods. Utilize our expertise ... Profiling Service or from your own ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
Biology Products: